Skip to main content
. 2018 Dec 14;3(3):351–358. doi: 10.1007/s41669-018-0110-3

Fig. 2.

Fig. 2

Cost-effectiveness plane. Observations shown are the results of probabilistic sensitivity analysis of the Markov model of lenalidomide in myelodysplastic syndrome deletion 5q [del(5q)], with WTP thresholds of £20,000 and £30,000 displayed for reference. QALY quality-adjusted life-year, WTP willingness to pay